Retina Technology

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

The diagnostic and monitoring tools use artificial intelligence-based models.

The COVID-19 pandemic changed medicine forever, and now scientists are forging a new path for healthcare in the future, including in ophthalmology.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The collaboration will bring automated, AI-powered OCT segmentation to MICRON Software Suite.

The company’s AI technology uses retinal imaging to assess potential health risks in patients.

Scientists at the National Institutes of Health use artificial intelligence called ‘P-GAN’ to improve next-generation imaging of cells in the back of the eye.

The company created this new role as they see continued growth and room for more expansion.

The company noted that individuals can purchase the ARx AI headset and register for access to the Seeing AI app through the provided links or download the latest version of the NaviLens app.

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

The collaboration combines Clario's transformative technology with Cleveland Clinic's market-leading imaging expertise and AI-enabled analysis to help bring new therapies to patients, faster.

Advances in virtual reality and AI are helping those with AMD and low vision.

ChatGPT-4 (OpenAI) had an overall “fair” performance when answering multiple-choice ophthalmic questions unrelated to multifocal imaging.

AI matched and outshone human specialists.

The platform to streamline clinical decision workflows, management of teleophthalmology, referral decisions and patient management while improving clinic efficiencies.

Toku’s AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images.

Massachusetts Eye and Ear researchers came up with a mobile app called All_Aboard, designed to be used along with mainstream GPS systems and focuses on improving micro-navigation.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

According to researchers at Johns Hopkins Children’s Center, AI-driven cameras take images of the back of the eye and require no eye drops can be used to close care gaps.

The American subsidiary of the German ophthalmic diagnostic device designer announced in a news release that its OCULUS Easyfield VR™ is now available in the US ophthalmic market

The app is a tool aimed at allowing patients to measure their visual acuity at home by themselves.

NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

By joining the group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD, RetinAI hopes to forge a global retinal imaging initiative targeting research in the disease.

The platform technology can be adapted to assess a vast array of biomarkers present in the eye.

The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.